Skip to main content

Table 2 Characteristics of included clinical trials in systematic review

From: Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review

Study Entry e status Sample size (n) Sex Median (range) age (y) Mean (range) weight (kg) Intervention
    Male Female LAM LdT LAM LdT LAM LdT
Lai 2005[6] HBeAg+ 63 49 14 34 (18-61) 40 (19-60) 69 (45-86) 70 (53-120) 19 44
  HBeAg- N/A N/A N/A N/A 41 (22-68) N/A 70 (51-96) N/A N/A
Lai 2007[7] HBeAg+ 921 684 237 33 (16-67) 32 (16-63) 68 (38-150) 66 (38-126) 463 458
  HBeAg- 446 351 95 43 (18-68) 43 (17-68) 71 (45-148) 72 (42-123) 224 222
Rasenack 2007[17] HBeAg+ 580 N/A N/A N/A N/A N/A N/A 289 291
Jia 2007[16] HBeAg+ 290 225 65 29 (15-63) 28 (16-64) 62 (42-96) 62 (43-93) 143 147
  HBeAg- 42 36 6 36 (19-58) 38 (20-56) 65 (49-93) 64 (52-99) 22 20
Hou 2008[10] HBeAg+ 290 225 65 29 (15-63) 28 (16-64) 62 (42-96) 62 (43-93) 143 147
  HBeAg- 42 36 6 36 (19-58) 38 (20-56) 65 (49-93) 64 (52-99) 22 20
Liaw 2009[15] HBeAg+ 921 684 237 33 (16-67) 32 (16-63) 68 (38-150) 66 (38-126) 463 458
  HBeAg- 446 351 95 43 (18-68) 43 (17-68) 71 (45-148) 72 (42-123) 224 222
Cai 2009[13] HBeAg+ 36 34 11 33.62 ± 11.17 29.59 ± 10.17 N/A N/A 19 17
  HBeAg- 9      N/A N/A 4 5
Yang 2009[14] HBeAg+ 40 62 38 47.9 ± 8.6   N/A N/A 50 50
  HBeAg- 60      N/A N/A   
Zhong 2009[11] HBeAg+ 120 81 39 30 ± 8.5 29 ± 8.2 61 ± 13.6 62 ± 14.2 60 60
  HBeAg- 120 72 48 42 ± 9.5 41 ± 10.1 64 ± 15.2 63 ± 14.5 60 60
Chen 2009[9] HBeAg+ 73 62 11 27.9(16-46)   N/A N/A 43 30
Tang 2009[8] HBeAg+ 108 N/A N/A N/A N/A N/A N/A 52 56
  HBeAg- 56 N/A N/A N/A N/A N/A N/A 27 29